Sandbox/AL: Difference between revisions
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{ | {{Fondaparinux}} | ||
{{CMG}}; {{AE}} {{AZ}} | {{CMG}}; {{AE}} {{AZ}} | ||
'''''For patient information, click <u>[[Fondaparinux (patient information)|here]]'''''</u>. | |||
'''''For patient information | {{SB}} Arixtra<sup>®</sup> | ||
{{SB}} | |||
==Overview== | ==Overview== | ||
'''Fondaparinux''' (trade name '''Arixtra''') is an [[anticoagulant]] medication chemically related to [[low molecular weight heparin]]s. It is marketed by [[GlaxoSmithKline]]. A generic version developed by Alchemia is marketed within the US by [[Dr. Reddy's Laboratories]]. | |||
==Category== | ==Category== | ||
[[Factor Xa]] inhibitors. | |||
==FDA Package Insert== | ==FDA Package Insert== | ||
===Arixtra<sup>®</sup>=== | |||
'''| [[Fondaparinux indications and usage|Indications and Usage]]''' | |||
'''| [[Fondaparinux dosage and administration|Dosage and Administration]]''' | |||
'''| [[Fondaparinux dosage forms and strengths|Dosage Forms and Strengths]]''' | |||
'''| [[Fondaparinux contraindications|Contraindications]]''' | |||
'''| [[Fondaparinux warnings|Warnings and Precautions]]''' | |||
'''| [[Fondaparinux adverse reactions|Adverse Reactions]]''' | |||
'''| [[Fondaparinux drug interactions|Drug Interactions]]''' | |||
'''| [[Fondaparinux use in specific populations|Use in Specific Populations]]''' | |||
'''| [[Fondaparinux overdosage|Overdosage]]''' | |||
'''| [[Fondaparinux description|Description]]''' | |||
'''| [[Fondaparinux clinical pharmacology|Clinical Pharmacology]]''' | |||
'''| [[Fondaparinux nonclinical toxicology|Nonclinical Toxicology]]''' | |||
'''| [[Fondaparinux clinical studies|Clinical Studies]]''' | |||
'''| [[Fondaparinux how supplied storage and handling|How Supplied/Storage and Handling]]''' | |||
'''| [[Fondaparinux patient counseling information|Patient Counseling Information]]''' | |||
'''| [[Fondaparinux labels and packages|Labels and Packages]]''' | |||
[[image:fond.png]] | |||
==Mechanism of Action== | ==Mechanism of Action== | ||
The antithrombotic activity of fondaparinux sodium is the result of [[antithrombin]] III (ATIII)-mediated selective inhibition of [[Factor Xa]]. By selectively binding to ATIII, fondaparinux sodium potentiates (about 300 times) the innate neutralization of Factor Xa by ATIII. Neutralization of Factor Xa interrupts the blood coagulation cascade and thus inhibits [[thrombin ]]formation and thrombus development. | |||
Fondaparinux sodium does not inactivate thrombin (activated Factor II) and has no known effect on platelet function. At the recommended dose, fondaparinux sodium does not affect[[ fibrinolytic ]]activity or bleeding time.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ARIXTRA (FONDAPARINUX SODIUM) INJECTION, SOLUTION [GLAXOSMITHKLINE LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=05bb2dd4-5fb5-4ec9-29a8-d200e62d1a8f | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Cardiovascular Drugs]] | |||
[[Category:Drugs]] | [[Category:Drugs]] |
Revision as of 13:43, 7 July 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2] For patient information, click here. Synonyms / Brand Names: Arixtra®
Overview
Fondaparinux (trade name Arixtra) is an anticoagulant medication chemically related to low molecular weight heparins. It is marketed by GlaxoSmithKline. A generic version developed by Alchemia is marketed within the US by Dr. Reddy's Laboratories.
Category
Factor Xa inhibitors.
FDA Package Insert
Arixtra®
| Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages
Mechanism of Action
The antithrombotic activity of fondaparinux sodium is the result of antithrombin III (ATIII)-mediated selective inhibition of Factor Xa. By selectively binding to ATIII, fondaparinux sodium potentiates (about 300 times) the innate neutralization of Factor Xa by ATIII. Neutralization of Factor Xa interrupts the blood coagulation cascade and thus inhibits thrombin formation and thrombus development.
Fondaparinux sodium does not inactivate thrombin (activated Factor II) and has no known effect on platelet function. At the recommended dose, fondaparinux sodium does not affectfibrinolytic activity or bleeding time.[1]